These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16276000)

  • 1. Subsieve-size agarose capsules enclosing ifosfamide-activating cells: a strategy toward chemotherapeutic targeting to tumors.
    Sakai S; Kawabata K; Tanaka S; Harimoto N; Hashimoto I; Mu C; Salmons B; Ijima H; Kawakami K
    Mol Cancer Ther; 2005 Nov; 4(11):1786-90. PubMed ID: 16276000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small agarose microcapsules with cell-enclosing hollow core for cell therapy: transplantation of Ifosfamide-activating cells to the mice with preestablished subcutaneous tumor.
    Sakai S; Hashimoto I; Tanaka S; Salmons B; Kawakami K
    Cell Transplant; 2009; 18(8):933-9. PubMed ID: 19500478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450.
    Löhr M; Müller P; Karle P; Stange J; Mitzner S; Jesnowski R; Nizze H; Nebe B; Liebe S; Salmons B; Günzburg WH
    Gene Ther; 1998 Aug; 5(8):1070-8. PubMed ID: 10326030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biocompatibility of subsieve-size capsules versus conventional-size microcapsules.
    Sakai S; Mu C; Kawabata K; Hashimoto I; Kawakami K
    J Biomed Mater Res A; 2006 Aug; 78(2):394-8. PubMed ID: 16680700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of subsieve-size capsules and application to cell therapy.
    Sakai S; Kawakami K
    Adv Exp Med Biol; 2010; 670():22-30. PubMed ID: 20384215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of mammalian cell-enclosing subsieve-size agarose capsules (<100 microm) for cell therapy.
    Sakai S; Kawabata K; Ono T; Ijima H; Kawakami K
    Biomaterials; 2005 Aug; 26(23):4786-92. PubMed ID: 15763258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors.
    Müller P; Jesnowski R; Karle P; Renz R; Saller R; Stein H; Püschel K; von Rombs K; Nizze H; Liebe S; Wagner T; Günzburg WH; Salmons B; Löhr M
    Ann N Y Acad Sci; 1999 Jun; 880():337-51. PubMed ID: 10415878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microencapsulated, CYP2B1-transfected cells activating ifosfamide at the site of the tumor: the magic bullets of the 21st century.
    Löhr M; Hummel F; Faulmann G; Ringel J; Saller R; Hain J; Günzburg WH; Salmons B
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S21-4. PubMed ID: 12042985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
    Lengler J; Omann M; Düvier D; Holzmüller H; Gregor W; Salmons B; Günzburg WH; Renner M
    Biochem Pharmacol; 2006 Sep; 72(7):893-901. PubMed ID: 16887103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted intraabdominal chemotherapy for peritoneal carcinomatosis.
    Samel S; Löhr M
    Cancer Treat Res; 2007; 134():469-82. PubMed ID: 17633075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
    Chen L; Waxman DJ; Chen D; Kufe DW
    Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-arterial instillation of microencapsulated, Ifosfamide-activating cells in the pig pancreas for chemotherapeutic targeting.
    Kröger JC; Benz S; Hoffmeyer A; Bago Z; Bergmeister H; Günzburg WH; Karle P; Klöppel G; Losert U; Müller P; Nizze H; Obermaier R; Probst A; Renner M; Saller R; Salmons B; Schwendenwein I; von Rombs K; Wiessner R; Wagner T; Hauenstein K; Löhr M
    Pancreatology; 2003; 3(1):55-63. PubMed ID: 12649565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy.
    Karle P; Müller P; Renz R; Jesnowski R; Saller R; von Rombs K; Nizze H; Liebe S; Günzburg WH; Salmons B; Löhr M
    Adv Exp Med Biol; 1998; 451():97-106. PubMed ID: 10026857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer.
    Günzburg WH; Salmons B
    Acta Biochim Pol; 2005; 52(3):601-7. PubMed ID: 16175235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine.
    Kammertoens T; Gelbmann W; Karle P; Alton K; Saller R; Salmons B; Günzburg WH; Uckert W
    Cancer Gene Ther; 2000 Apr; 7(4):629-36. PubMed ID: 10811482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide.
    Samel S; Keese M; Lux A; Jesnowski R; Prosst R; Saller R; Hafner M; Sturm J; Post S; Löhr M
    Cancer Gene Ther; 2006 Jan; 13(1):65-73. PubMed ID: 16096652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.
    Chen CS; Lin JT; Goss KA; He YA; Halpert JR; Waxman DJ
    Mol Pharmacol; 2004 May; 65(5):1278-85. PubMed ID: 15102956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral activation of cyclophosphamide by retroviral transfer of the cytochrome P450 2B1 in a pancreatic tumor model. Combination with the HSVtk/GCV system.
    Carrió M; Visa J; Cascante A; Estivill X; Fillat C
    J Gene Med; 2002; 4(2):141-9. PubMed ID: 11933215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a human cell clone expressing cytochrome P450 for safe use in human somatic cell therapy.
    Günzburg WH; Karle P; Renz R; Salmons B; Renner M
    Ann N Y Acad Sci; 1999 Jun; 880():326-36. PubMed ID: 10415877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
    Chen L; Waxman DJ
    Cancer Res; 1995 Feb; 55(3):581-9. PubMed ID: 7834628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.